Today: 30 June 2026

Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy

Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy

New York, Feb 7, 2026, 17:35 EST — Market’s done for the day. Abbott Laboratories edged up 1.6% to finish at $110.83 on Friday, notching a back-to-back advance. The stock lagged behind the S&P 500’s 1.97% jump and the Dow’s 2.47% rally. Abbott is still trading 21.53% under its 52-week peak at $141.23. Volume came in at 9.9 million shares, above the 50-day average of 8.9 million.
8 February 2026
·
AT&T stock heads into Monday after $6.5 billion bond sale and new kid-focused phone launch

AT&T stock heads into Monday after $6.5 billion bond sale and new kid-focused phone launch

New York, Feb 7, 2026, 17:41 EST — The session wrapped up with markets closed. AT&T Inc shares slipped 0.7%, ending Friday at $27.13, after a regulatory filing outlined the telecom giant’s $6.5 billion bond offering. The debt was sliced into five tranches with maturities spanning 2031 to 2056. Coupon rates run from 4.4% up to 6.0%. BofA Securities, Deutsche Bank, Morgan Stanley, MUFG, TD Securities and Wells Fargo handled the underwriting, according to the filing.
8 February 2026
·
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

COPENHAGEN, February 7, 2026, 23:19 CET — The market is closed. Novo Nordisk A/S Class B shares could see renewed attention Monday, after Hims & Hers said it's pulling the $49 compounded Wegovy pill, responding to U.S. regulators. Novo’s Copenhagen-listed stock closed out Friday at 295.50 crowns, climbing 5.3%, Reuters data showed.
7 February 2026
··
1 … 485 486 487 488 489 … 2,123

Stock Market Today

  • Electro Optic Systems (ASX:EOS) jumps 5.6% on S&P/ASX 200 move, outlook mixed
    June 30, 2026, 6:57 AM EDT. Shares in Electro Optic Systems Holdings (ASX: EOS) rose 5.6% after the stock was added to both the S&P/ASX 200 and Industrials Sector indices, raising its profile and boosting liquidity. The news could pull in flows from index funds and more institutional money. EOS makes counter drone, laser, and space control tech, aiming to turn defense deals into steady revenue. A recent €10 million investment in a European AI-based drone defense hub fits this plan. Still, the company faces recurring risks around its heavy dependence on big defense contracts and swings in financials. Market forecasts point to A$514.7 million revenue and A$62.6 million earnings by 2029, with some analysts seeing about 26% upside to fair value near A$12.94. But analyst views are split, and the outlook remains unsettled as the story develops.
Go toTop